Trial Profile
A Phase I, Double-blind, Randomised, Single-dose, Parallel Group Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD204 and Bevacizumab (Avastin) in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Acronyms SAMSON; Samson1
- Sponsors Prestige BioPharma
- 31 May 2020 Results assessing quality and clinical similarity (pharmacokinetic and safety) of HD204 in healthy males, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jul 2019 Primary endpoint has been met. (Area under Curve (AUC, Pharmacokinetics)), according to a Prestige BioPharma media release.
- 08 Jul 2019 According to a Prestige BioPharma media release, the top line results from this study will be presented at the ESMO 2019.